Everything below concerns MC1R. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-14. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
== History == April 2016: initiation of Phase 2b trial December 2017: initiation of JADE Mono-1 Phase 3 trial May 2018: Results of Phase 2b trial posted October 2019: Results of Phase 3 trial presented June 2020: Results of second Phase 3 trial published The US Food and Drug Administration (FDA) approved abrocitinib based on evidence from three controlled clinical trials enrolling a total of 1615 participants supporting efficacy and safety. Two of the trials enrolled participants twelve years of age and older with moderate-to-severe atopic dermatitis and one trial enrolled adults with moderate-to-severe atopic dermatitis. The trials were conducted at multiple sites in 18 countries (i.e., United States, Canada, Australia, Mexico, Chile, Great Britain, Poland, Germany, Bulgaria, Hungary, Czech Republic, Latvia, Slovakia, Spain, Italy, Japan, Korea, Taiwan). In addition, safety analyses were performed on the combined results of these 3 controlled clinical trials and one additional controlled study in a total of 1,540 participants. All three trials evaluated two doses of abrocitinib: 100 mg and 200 mg. The monotherapy trials were identically designed, 16-week, randomized, multicenter, double-blind, placebo-controlled, parallel group, phase 3 trials. Trial-AD-3 with concomitant background therapy was a 24-week, multicenter, randomized, double-blind, active-comparator (dupilumab) and placebo-controlled, phase 3 trial.
== Soundtrack == The Out Cold soundtrack is a 12-track compilation of songs from the film. It is available on the RCA record label. The Weezer song "Island in the Sun" plays an important part in the film but is left off the soundtrack.
=== Osmotic drying using a humectant === Osmotic dehydration is the process of soaking food in highly concentrated solutions of humectant. Salt and sugar are commonly used humectants for this process. Water diffusion from the food to the humectant solution is caused by osmotic pressure. The water is replaced by the humectant, which results in a lowered water activity for the food product. Osmotic dehydration process results in two way mass transfer in regards to the moisture lost and the solids gained, with moisture loss being much greater than the addition of solids. Advantages of osmotic dehydration include low processing temperatures, short drying times, and 20-30% lower energy consumption than typical dehydration processes. Sugar is used as the humectant for candied intermediate moisture fruits, and salt is used for intermediate moisture vegetables and fish. Additionally, a mixture of humectants can be formulated to manipulate the sensory properties of the food product. Osmotic drying using a humectant results in a soft texture in the final product.
===== MeSH D08.811.682.660 – oxidoreductases acting on ch-ch group donors ===== MeSH D08.811.682.660.150 – acyl-coa dehydrogenases MeSH D08.811.682.660.150.100 – acyl-coa dehydrogenase MeSH D08.811.682.660.150.150 – acyl-coa dehydrogenase, long-chain MeSH D08.811.682.660.150.200 – acyl-CoA oxidase MeSH D08.811.682.660.150.300 – butyryl-coa dehydrogenase MeSH D08.811.682.660.200 – cholestenone 5alpha-reductase MeSH D08.811.682.660.250 – coproporphyrinogen oxidase MeSH D08.811.682.660.275 – dihydrodipicolinate reductase MeSH D08.811.682.660.300 – dihydroorotate oxidase MeSH D08.811.682.660.325 – dihydrouracil dehydrogenase (nad+) MeSH D08.811.682.660.350 – dihydrouracil dehydrogenase (nadp) MeSH D08.811.682.660.385 – electron transport complex ii MeSH D08.811.682.660.385.500 – succinate dehydrogenase MeSH D08.811.682.660.387 – enoyl-(acyl-carrier-protein) reductase (nadh) MeSH D08.811.682.660.390 – enoyl-(acyl-carrier protein) reductase (nadph, b-specific) MeSH D08.811.682.660.425 – Glutaryl-CoA dehydrogenase MeSH D08.811.682.660.462 – isovaleryl-coa dehydrogenase MeSH D08.811.682.660.490 – 15-oxoprostaglandin 13-reductase MeSH D08.811.682.660.500 – prephenate dehydrogenase MeSH D08.811.682.660.600 – protoporphyrinogen oxidase MeSH D08.811.682.660.750 – succinate dehydrogenase MeSH D08.811.682.660.900 – testosterone 5-alpha-Reductase
Biomedical Sciences Molecular and Cellular Biology Bioengineering and Devices Biophysics, Biochemistry and Structural Biology Climate science, Agriculture and Environment Biotechnology Regulatory Affairs, IPR and Policy
Sources: en.wikipedia.org
=== Laver Cup === Zverev took part in the inaugural Laver Cup in Prague in 2017. He accrued four points by winning both of his singles matches for Team Europe as they defeated Team World 15–9. He played a more crucial role in 2018 and 2019, winning the clinching matches in both editions against Kevin Anderson and Milos Raonic respectively. In the 2021 edition in Boston, he defeated John Isner in three sets in his only match in Team Europe's 14–1 win. In 2024, Zverev returned to the Laver Cup after a two-year absence in which Team World had won both editions. He lost his first match to Taylor Fritz, but rebounded on the third day to win against Frances Tiafoe in a deciding match tie-break. In 2025, Zverev failed to win any matches against Team World, losing in straight sets to Alex de Minaur and Taylor Fritz, the latter contributing his sixth consecutive loss against the American and allowing Team World to secure their third Laver Cup title.
==== Cossack autonomies in Don, Kuban and North Caucasus ==== Soon after the Bolsheviks seized power in Petrograd on 7–8 November 1917, most Cossack atamans and their government refused to recognize the legitimacy of the new regime. The Don Cossack ataman, Aleksey Kaledin, went as far as to invite opponents of the Bolsheviks to the Don Host. But the position of many Cossack governments was far from secure, even within the boundaries of their hosts. In some areas, soviets formed by outlanders and soldiers rivaled the Cossack government, and ethnic minorities also tried to acquire a measure of self-rule. Even the Cossack communities themselves were divided, as the atamans tended to represent the interests of prosperous landowners and the officer corps. Poorer Cossacks, and those serving in the army, were susceptible to Bolshevik propaganda promising to spare "toiling Cossacks" from land appropriation. The unwillingness of rank-and-file Cossacks to vigorously defend the Cossack government enabled the Red Army to occupy the vast majority of Cossack lands by late spring of 1918. But the Bolsheviks' policy of requisitioning grain and foodstuffs from the countryside to supply Russia's starving northern cities quickly fomented revolt among Cossack communities. These Cossack rebels elected new atamans and made common cause with other anticommunist forces, such as the Volunteer Army in South Russia. Subsequently, the Cossack homelands became bases for the White movement during the Russian Civil War.
=== Prevention of Oxidative Damage === Cellular defenses against the damaging effects of oxidative stress involve both enzymatic and nonenzymatic components. The enzymatic components may directly scavenge active oxygen species or may act by producing the nonenzymatic antioxidants. There are four enzymes that provide the bulk of protection against deleterious reactions involving active oxygen in bacteria: SODs (superoxide dismutases encoded by sodA and sodB), catalases (katE and katG), glutathione synthetase (gshAB) and glutathione reductase (gor). Some bacteria have NADH-dependent peroxidases specific for H2O2. The main nonenzymatic antioxidants in E. coli are GSH and thioredoxin (encoded by trxA). Ubiquinone and menaquinone may also serve as membrane-associated antioxidants.
The electron density in cyanogen bromide is shifted away from the carbon atom, making it unusually electrophilic, and towards the more electronegative bromine and nitrogen. This leaves the carbon particularly vulnerable to attack by a nucleophile, and the cleavage reaction begins with a substitution reaction in which bromine is ultimately replaced by the sulfur in methionine. This attack is followed by the formation of a five-membered ring as opposed to a six-membered ring, which would entail the formation of a double bond in the ring between nitrogen and carbon. This double bond would result in a rigid ring conformation, thereby destabilizing the molecule. Thus, the five-membered ring is formed so that the double bond is outside the ring, as shown in the figure. Although the nucleophilic sulfur in methionine is responsible for attacking BrCN, the sulfur in cysteine does not behave similarly. If the sulfur in cysteine attacked cyanogen bromide, the bromide ion would deprotonate the cyanide adduct, leaving the sulfur uncharged and the beta carbon of the cysteine not electrophilic. The strongest electrophile would then be the cyanide carbon, which, if attacked by water, would yield cyanic acid and the original cysteine.
Sources: en.wikipedia.org
=== Extraterrestrial pathogens === Hoyle and Wickramasinghe have advanced the argument that various outbreaks of illnesses on Earth are of extraterrestrial origins, including the 1918 flu pandemic and certain outbreaks of polio and mad cow disease. For the 1918 flu pandemic they hypothesised that cometary dust brought the virus to Earth simultaneously at multiple locations—a view almost universally dismissed by external experts on this pandemic. On 24 May 2003 The Lancet published a letter from Wickramasinghe, jointly signed by Milton Wainwright and Jayant Narlikar, in which they hypothesised that the virus that causes severe acute respiratory syndrome (SARS) could be extraterrestrial in origin instead of originating from chickens. The Lancet subsequently published three responses to this letter, showing that the hypothesis was not evidence-based, and casting doubts on the quality of the experiments referenced by Wickramasinghe in his letter. Claims connecting terrestrial disease and extraterrestrial pathogens have been rejected by the scientific community. In 2020, Wickramasinghe and colleagues published a paper claiming that Severe acute respiratory syndrome coronavirus 2, the virus responsible for the COVID-19 pandemic was also of extraterrestrial origin, the claim was criticised for lacking evidence.
=== Thirlwall inquiry === After Letby's conviction, the British government announced an independent inquiry into "the circumstances surrounding the deaths and incidents, including how concerns raised by clinicians were dealt with". It was initially established on a non‑statutory basis, meaning witnesses could not be compelled to give evidence and inquests would still be required. Senior figures at the Countess of Chester Hospital, including the medical director, chief executive and nursing director at the time of the incidents, said they would cooperate. The medical director retired in August 2018, and the chief executive resigned the following month after signing a non‑disclosure agreement. Families represented by the law firm Slater and Gordon called for the inquiry to be given statutory powers, arguing that a non‑statutory process relied on the goodwill of witnesses. Similar calls were made by former Justice Secretary Sir Robert Buckland, Chester MP Samantha Dixon, Steve Brine, chair of the Health and Social Care Select Committee, Sir Keir Starmer, then Leader of the Opposition, and the Parliamentary and Health Service Ombudsman. In August 2024, a group of 24 neonatal and statistical experts wrote to ministers requesting that the inquiry be postponed and its terms amended, citing concerns about the safety of Letby's convictions. The inquiry declined to make changes. Education Secretary Gillian Keegan said the type of inquiry would be reviewed once a chair was appointed.
=== Sympathetic hyperactivation === Hyperactivation of the sympathetic nervous system is not a recognized condition in itself, but it is a component of a number of conditions, as well as a possible consequence of taking sympathomimetic drugs. It causes a distinctive set of symptoms including aches and pains, rapid heartbeat, elevated blood pressure, sweating, palpitations, anxiety, headache, paleness, and a drop in blood glucose. If sympathetic activity is elevated for an extended time, it can cause weight loss and other stress-related body changes. The list of conditions that can cause sympathetic hyperactivation includes severe brain injury, spinal cord damage, heart failure, high blood pressure, kidney disease, and various types of stress.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.